In a filing, ARS Pharmaceuticals Inc revealed its Chief Legal Officer Fitzpatrick Alexander A unloaded Company’s shares for reported $1.45 million on May 20 ’25. In the deal valued at $14.10 per share,102,969 shares were sold. As a result of this transaction, Fitzpatrick Alexander A now holds 89,613 shares worth roughly $1.3 million.
Then, SAUNDERS BRENT L sold 120,000 shares, generating $1,710,024 in total proceeds. Upon selling the shares at $14.25, the Director now owns 0 shares.
Before that, Scott Kathleen D. sold 50,000 shares. ARS Pharmaceuticals Inc shares valued at $705,165 were divested by the Chief Financial Officer at a price of $14.10 per share. As a result of the transaction, Scott Kathleen D. now holds 7,424 shares, worth roughly $0.11 million.
Scotiabank initiated its ARS Pharmaceuticals Inc [SPRY] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $30. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Cantor Fitzgerald began covering SPRY with “an Overweight” recommendation on August 20, 2024. Raymond James revised its rating on August 13, 2024. It rated SPRY as “a Strong buy” which previously was an “an Outperform”.
Price Performance Review of SPRY
On Monday, ARS Pharmaceuticals Inc [NASDAQ:SPRY] saw its stock jump 0.28% to $14.53. Over the last five days, the stock has gained 0.48%. ARS Pharmaceuticals Inc shares have risen nearly 37.73% since the year began. Nevertheless, the stocks have risen 59.50% over the past one year. While a 52-week high of $18.51 was reached on 05/29/25, a 52-week low of $7.55 was recorded on 03/04/25. SMA at 50 days reached $13.90, while 200 days put it at $13.28.
Levels Of Support And Resistance For SPRY Stock
The 24-hour chart illustrates a support level at 14.20, which if violated will result in even more drops to 13.88. On the upside, there is a resistance level at 14.86. A further resistance level may holdings at 15.20. The Relative Strength Index (RSI) on the 14-day chart is 53.77, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.33, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 43.69%. Stochastics %K at 48.12% indicates the stock is a holding.
The most recent change occurred on August 12, 2024 when Leerink Partners resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $20.
